Malin Corporation | MLC - Cash And Equivalent


Malin Corporation reported EUR62.1M in Cash and Equivalent for its fiscal semester ending in December of 2024.





Cash And Equivalent Change Date
Akebia Therapeutics USD 162.64M 22.2M Mar/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
ALKERMES USD 351.55M 37.02M Mar/2026
Avita Medical AUD 10.24M 1.98M Dec/2025
Dianthus Therapeutics USD 627.67M 576.58M Mar/2026
Eurofins Scientific SE EUR 791.2M 37.9M Dec/2025
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
IQVIA Holdings USD 1.95B 33M Mar/2026
Lonza CHF 719M 188M Dec/2025
Malin Corporation EUR 62.1M 26.4M Dec/2024
Moderna USD 1.91B 687M Mar/2026
Organon & Co USD 1.12B 542M Mar/2026
Revvity USD 860.32M 59.54M Mar/2026
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Viatris USD 1.8B 481.8M Mar/2026
Xeris Pharmaceuticals USD 111.75M 708K Mar/2026